941604-37-1

Basic information

• Product Name: tert-butyl 6-bromo-2-oxo-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxylate
• Synonyms: tert-butyl 6-bromo-2-oxo-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxylate
• CAS NO: 941604-37-1
• Molecular Weight: 396.284
• Mol File: 941604-37-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl 6-bromo-2-oxo-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 6-bromo-2-oxo-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxylate(941604-37-1)
• EPA Substance Registry System: tert-butyl 6-bromo-2-oxo-2,4-dihydro-1H-spiro[[1,8]naphthyridine-3,4'-piperidine]-1'-carboxylate(941604-37-1)

Safety Data

• Hazardous Substances Data: 941604-37-1(Hazardous Substances Data)

Upstream product

• 443956-55-6 (2-amino-5-bromopyridine-3-yl)methanol hydrobromide 
• 1309208-12-5 1-tert-butyl 4-ethyl 4-((2-amino-5-bromopyridin-3-yl)methyl)piperidin-1,4-dicarboxylate 
• 335031-01-1 2-amino-5-bromo-3-(hydroxymethyl)pyridine 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 335033-38-0 2-amino-5-bromo-3-(bromomethyl)pyridine hydrobromide 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1126-09-6 4-carbethoxypiperidine 
• 23612-57-9 (2-amino-3-pyridinyl)methanol 

Downstream Products

• 941604-38-2 (E)-benzyl 3-[7-oxo-(4'-N-Boc-6-spiropiperidinyl)-1,8-naphthyridin-3-yl]acrylate 

Relevant articles and documents

SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS

The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors. Formula(I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME

In part, the present invention is directed towards compounds with FabI inhibiting properties. Such compounds may also inhibit other enzymes, including those similar to FabI either structurally or functionally, for example, Fab K. Kits and compositions that include the disclosed compounds are also provided. Methods of treating a subject with a bacterial illness is also disclosed.